Does heaven exist? With well over 100,000 plus recorded and described spiritual experiences collected over 15 years, to base the answer on, science can now categorically say yes. Furthermore, you can see the evidence for free on the website allaboutheaven.org.

Available on Amazon
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)


This book, which covers Visions and hallucinations, explains what causes them and summarises how many hallucinations have been caused by each event or activity. It also provides specific help with questions people have asked us, such as ‘Is my medication giving me hallucinations?’.

Available on Amazon
also on all local Amazon sites, just change .com for the local version (.co.uk, .jp, .nl, .de, .fr etc.)

Observations placeholder

Chromium, insulin and diabetes



Type of Spiritual Experience


This paper needs to be read very very carefully.

It shows not that chromium is good for the obese or good for diabetes, but that in certain conditions of possible chromium deficiency leading to disruption of glucose processing, chromium - the non toxic kind! - has a beneficial effect.

A description of the experience

Am J Health Syst Pharm. 2010 Apr 1;67(7):535-41. doi: 10.2146/ajhp090109. Improved glucose control associated with i.v. chromium administration in two patients receiving enteral nutrition.  Phung OJ, Quercia RA, Keating K, Baker WL, Bell JL, White CM, Coleman CI. University of Connecticut (UC)/Hartford Hospital (HH) Evidence-Based Practice Center, Hartford, CT 06102-5037, USA.

PURPOSE: The effect of i.v. chromium administration on glucose control in two patients receiving enteral nutrition is described.

SUMMARY: Chromium supplementation has been hypothesized to potentiate the actions of insulin in facilitating cellular uptake of glucose.

We report two cases-one involving a diabetic patient and the other a nondiabetic patient-in which chromium administration appeared to decrease insulin requirements.

In case 1, a diabetic patient given a single course of chromic chloride appeared to have a probable response to the drug. Within the first day of chromic chloride administration, insulin requirements declined. When chromic chloride was discontinued, insulin requirements did not rise, suggesting efficacy and sustained effect. The patient's glucose intake and blood glucose levels remained relatively stable, while there was a significant decline in insulin requirements. Serum chromium levels were not assessed, so it is uncertain if the patient experienced chromium deficiency or if it was adequately treated with chromium supplementation, and a dose-response relationship could not be ascertained because the patient received a continuous infusion of chromium.

In case 2, the insulin requirements of a nondiabetic patient appeared to decrease in response to multiple courses of chromic chloride. Upon initial discontinuation of chromic chloride, the patient's lower insulin requirements were sustained for a few days, but changes in clinical status and other medications precipitated elevated insulin requirements and the need for subsequent chromic chloride administration. Further research in more controlled settings is necessary to elucidate chromium's effect on insulin requirements.

CONCLUSION: Infusion of chromic chloride appeared to reduce insulin requirements in one diabetic patient and one nondiabetic patient.

PMID: 20237381

The source of the experience

Other ill or disabled person

Concepts, symbols and science items



Science Items


Activities and commonsteps